Drug intelligence / Profile preview

venlafaxine + mirtazapine

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

Venlafaxine + mirtazapine is a combination of two antidepressant medications used primarily for the treatment of major depressive disorder, particularly in patients with treatment-resistant or refractory depression. Venlafaxine is a serotonin-norepinephrine reuptake inhibitor (SNRI) that increases levels of serotonin and norepinephrine in the brain by inhibiting their reuptake. Mirtazapine is classified as a noradrenergic and specific serotonergic antidepressant (NaSSA); it enhances central noradrenergic and serotonergic activity mainly through antagonism of central presynaptic alpha-2 adrenergic inhibitory autoreceptors and heteroreceptors, as well as antagonism at certain serotonin receptors (notably 5-HT2 and 5-HT3). The rationale for combining these agents lies in their complementary mechanisms, which may provide synergistic effects on neurotransmitter systems involved in mood regulation. Clinical studies suggest this combination can yield higher response rates than monotherapy for difficult-to-treat depression, though side effects such as sedation and weight gain are common[1][2][4][6].

Brand names
RemeronEffexor XR
Other names
California rocket fuel
02

Targets

HTR3A (5-hydroxytryptamine receptor 3A)HRH1 (Histamine H1 Receptor)HTR2A (Serotonin receptor 5-HT2A)ADRA2A (α2A)SERT (Sodium-dependent serotonin transporter)HTR2C (5-hydroxytryptamine 2C receptor)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on venlafaxine + mirtazapine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on venlafaxine + mirtazapine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call